干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现

免费注册账号
查看全文和研发动态、知识导航以及收藏您喜欢的数据等操作,您需要注册一个免费帐户并登录。

写笔记

您最近的笔记
Drug Name:umbilical cord blood-derived cytokine-induced killer cells (solid tumor), Zhongyuan Union/Alliancells
Regulatory Designations:     
Originator Company: VCANBIO Cell & Gene Engineering Corp Ltd Active Companies:
Last Change Date: 2019-01-17

extract

As no development has been reported for some time, this program is assumed to be discontinued. Zhongyuan Union Stem Cell Bio-Engineering , via its subsidiary Alliancells-PuRui Bioscience , was developing cord blood-derived cytokine-induced killer (CIK) cells for the potential treatment of solid tumors. In July 2013, a phase I trial was being planned. In April 2015, recruitment was started in China. At that time, trial completion was expected in June 2016 [ 1586517 ].


Other Drug Names:

human umbilical cord blood-derived cytokine-induced killer cells (solid tumor), Zhongyuan Union Stem Cell Bio-Engineering/Alliancells-PuRui Bioscience; umbilical cord blood-derived cytokine-induced killer cells (solid tumor), Zhongyuan Union/Alliancells

Technologies

Biological therapeutic; Cell therapy; Infusion; Intravenous formulation; Lymphocyte

Development Status (Current)

VCANBIO Cell & Gene Engineering Corp Ltd: China: No Development Reported: Solid tumor: 16-Oct-2016 Alliancells-PuRui Bioscience Co Ltd: China: No Development Reported: Solid tumor: 16-Oct-2016

Development Status (History)

Alliancells-PuRui Bioscience Co Ltd: China: Discovery: Solid tumor: 30-Jul-2013 VCANBIO Cell & Gene Engineering Corp Ltd: China: Discovery: Solid tumor: 30-Jul-2013 Alliancells-PuRui Bioscience Co Ltd: China: Phase 1 Clinical: Solid tumor: 15-Apr-2015 VCANBIO Cell & Gene Engineering Corp Ltd: China: Phase 1 Clinical: Solid tumor: 15-Apr-2015

Drug Development Phase

[Solid tumor: No Development Reported: China Solid tumor: No Development Reported: China]

Therapy Area:

Cancer


Highest Status

No Development Reported


Target-based Actions


Other Actions

Anticancer; Natural killer cell stimulator


Active Indications